A Single Dose Evaluation of the Effects of Moderate (Child-Pugh Grade B) Hepatic Impairment on Deflazacort Pharmacokinetics
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Deflazacort (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
- Sponsors Marathon Pharmaceuticals
- 22 Feb 2015 Status changed from recruiting to completed according to ClinicalTrials.gov record.
- 14 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 12 Nov 2014 New trial record